

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 April 2009 (02.04.2009)

PCT

(10) International Publication Number
WO 2009/039969 A3

(51) International Patent Classification:

A61K 38/07 (2006.01) A61P 25/28 (2006.01)
A61K 38/08 (2006.01) A61P 31/00 (2006.01)
A61P 3/00 (2006.01) A61P 35/00 (2006.01)
A61P 9/00 (2006.01) A61P 37/00 (2006.01)
A61P 11/00 (2006.01) A61P 31/20 (2006.01)

(21) International Application Number:

PCT/EP2008/007511

(22) International Filing Date:

9 September 2008 (09.09.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

07017750.6 11 September 2007 (11.09.2007) EP

(71) Applicant (for all designated States except US): **MONDO-BIOTECH LABORATORIES AG** [LI/LI]; Herrengasse 21, FL-9490 Vaduz (LI).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BEVEC, Dorian** [DE/DE]; Kriegerstrasse 62, 82110 Germering (DE). **CAVALLI, Fabio** [CH/CH]; Via Pasquée 23, CH-6925 Gentilino (CH). **CAVALLI, Vera** [CH/CH]; Via Pasquée, 23, CH-6925 Gentilino (CH). **BACHER, Gerald** [DE/DE]; Masurenweg 5, 82110 Germering (DE).

(74) Agent: **ARTH, Hans-Lothar**; ABK Patent Attorneys, Jasminweg 9, 14052 Berlin (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

22 May 2009

(54) Title: USE OF A VLA-4 INHIBITOR TETRAPEPTIDE, ALONE OR IN COMBINATION WITH BPP-B, AS A THERAPEUTIC AGENT

(57) Abstract: The present invention is directed to the use of the peptide compound Phenylac-Leu-Asp-Phe-D-Pro-NH₂ as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Phenylac-Leu-Asp-Phe-D-Pro-NH₂ optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.



WO 2009/039969 A3

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2008/007511

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K38/07 A61K38/08 A61P3/00 A61P9/00 A61P11/00
A61P25/28 A61P31/00 A61P35/00 A61P37/00 A61P31/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, Sequence Search, CHEM ABS Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MOLOSSI S. ET AL.: "Blockade of VLA-4 integrin binding to fibronectin with connecting segment-1 peptide reduces accelerated coronary arteriopathy in rabbit cardiac allografts." J. CLIN. INVEST., vol. 95, no. 6, 1995, pages 2601-2610, XP002519188 see abstract, page 2602 right col. and page 2609	1,6,8-15
X	US 5 688 913 A (ARRHENIUS THOMAS S [US] ET AL) 18 November 1997 (1997-11-18) see abstract, col.22 line 66 to col.23 line 32, examples 4, 6-8 ----- -/--	1,6,8-15

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

13 March 2009

Date of mailing of the international search report

27/03/2009

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Merckling-Ruiz, V

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/007511

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	COTTON J ETAL: "Selective inhibition of the C-domain of angiotensin-I converting enzyme by bradykinin potentiating peptides" BIOCHEMISTRY,, vol. 41, 1 January 2002 (2002-01-01), pages 6065-6071, XP002516952 see abstract and page 6070 last -----	6,8-15
Y	FERNANDEZ J H: "Using bradykinin-potentiating peptide structures to develop new anti-hypertensive drugs" GENETICS AND MOLECULAR RESEARCH,, vol. 3, no. 4, 1 January 2004 (2004-01-01), pages 554-563, XP002516953 see abstract and page 559 -----	6,8-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2008/007511

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5688913	A	18-11-1997	AU 693143 B2 25-06-1998
		AU 1215695 A 27-06-1995	
		WO 9515973 A1 15-06-1995	